SHIMADA et al.

Atty. Dkt.: Q90951

Preliminary Amendment

Page 2

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the

application:

LISTING OF CLAIMS:

(original): An apoptosis-inducing agent, which contains a protein that interacts 1.

with a FUSE binding protein as an active ingredient.

(original): The apoptosis-inducing agent according to claim 1, wherein the 2.

protein interacting with the FUSE binding protein is:

a protein consisting of the amino acid sequence represented by SEQ ID NO: 2 in the

sequence listing;

a protein consisting of an amino acid sequence derived from the amino acid sequence

represented by SEQ ID NO: 2 in the sequence listing by deletion, substitution, or addition of one

or several amino acids and having apoptosis-inducing activity; or

a partial peptide thereof.

(original): An apoptosis-inducing agent, which contains a polynucleotide 3.

encoding a protein that interacts with an FUSE binding protein as an active ingredient.

(original): The apoptosis-inducing agent according to claim 3, wherein the 4.

polynucleotide encoding the protein that interacts with the FUSE binding protein is: a

polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 1 in the

sequence listing;

a polynucleotide hybridizing under stringent conditions to a polynucleotide consisting of a nucleotide sequence complementary to the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 1 in the sequence listing and encoding a protein having apoptosis-inducing activity; or

a partial fragment thereof.

- 5. (original): The apoptosis-inducing agent according to any one of claims 1 to 4, which has a form that allows it to be introduced into a cell.
- 6. (original): The apoptosis-inducing agent according to claim 5, wherein the form that allows introduction into a cell is a vector.
- 7. (currently amended): The apoptosis-inducing agent according to any one of claims 1 to 6 claim 1, which is used for treating cancer.
- 8. (currently amended): A method for inducing apoptosis, which is a method for inducing apoptosis in a cell that proliferates due to the expression of a c-myc gene and which comprises a step of causing the apoptosis-inducing agent according to any one of claims 1 to 7-claim 1 to come into contact with the cell.
 - 9. (original): The method according to claim 8, wherein the cell is a cancer cell.
- 10. (original): The method according to claim 8 or 9, wherein the cell is a cell within a mammalian body.
 - 11. (original): The method according to claim 10, wherein the mammal is a human.

SHIMADA et al. Atty. Dkt.: Q90951 Preliminary Amendment Page 4

- 12. (original): A method for treating cancer, wherein an effective dose of: a protein consisting of the amino acid sequence represented by SEQ ID NO: 2 in the sequence listing; a protein consisting of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 in the sequence listing by deletion, substitution, or addition of 1 or several amino acids and having apoptosis-inducing activity; or a partial peptide thereof is administered to a mammal.
- polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 1 in the sequence listing; a polynucleotide hybridizing under stringent conditions to a polynucleotide consisting of a nucleotide sequence complementary to the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 1 in the sequence listing and encoding a protein having apoptosis-inducing activity; or a fragment thereof is administered to a mammal.
- 14. (original): The method according to claim 12 or 13, wherein the mammal is a human.